ASR Vermogensbeheer N.V. Boosts Stock Holdings in Thermo Fisher Scientific Inc. $TMO

ASR Vermogensbeheer N.V. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 116,792 shares of the medical research company’s stock after buying an additional 12,541 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Thermo Fisher Scientific were worth $47,352,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in TMO. Vanguard Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock worth $16,659,627,000 after acquiring an additional 230,382 shares during the period. Amundi raised its holdings in shares of Thermo Fisher Scientific by 5.9% during the first quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock valued at $1,426,316,000 after acquiring an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock valued at $1,455,774,000 after buying an additional 115,463 shares during the period. Pictet Asset Management Holding SA increased its stake in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock valued at $1,432,816,000 after buying an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after buying an additional 329,974 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Raymond James Financial reissued an “outperform” rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $490.00 to $550.00 in a research report on Thursday, September 11th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. Finally, Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Fifteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $583.53.

Thermo Fisher Scientific Stock Up 9.6%

TMO stock opened at $531.69 on Thursday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $200.77 billion, a PE ratio of 30.75, a price-to-earnings-growth ratio of 2.63 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $616.57. The business has a 50-day simple moving average of $480.27 and a 200 day simple moving average of $447.56.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same period in the previous year, the business posted $5.37 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.